119 related articles for article (PubMed ID: 1376823)
1. Inhibition of granulocyte cAMP-phosphodiesterase by rolipram in vivo is not sufficient to protect the canine myocardium from reperfusion injury.
Simpson PJ; Schelm JA; Smallwood JK; Clay MP; Lindstrom TD
J Cardiovasc Pharmacol; 1992 Jun; 19(6):987-95. PubMed ID: 1376823
[TBL] [Abstract][Full Text] [Related]
2. The role of serotonin (5HT2) receptor blockade in myocardial reperfusion injury: effects of LY53857 in a canine model of myocardial infarction.
Simpson PJ; Schelm JA; Jakubowski JA; Smallwood JK
J Pharmacol Exp Ther; 1991 Sep; 258(3):979-85. PubMed ID: 1653847
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic defibrination with ancrod does not protect canine myocardium from reperfusion injury.
Simpson PJ; Schelm JA; Smith GF
J Pharmacol Exp Ther; 1991 Feb; 256(2):780-6. PubMed ID: 1704437
[TBL] [Abstract][Full Text] [Related]
4. Effects of zaprinast and rolipram on platelet aggregation and arrhythmias following myocardial ischaemia and reperfusion in anaesthetized rabbits.
Holbrook M; Coker SJ
Br J Pharmacol; 1991 Aug; 103(4):1973-9. PubMed ID: 1655149
[TBL] [Abstract][Full Text] [Related]
5. Effects of SCA40 on human isolated bronchus and human polymorphonuclear leukocytes: comparison with rolipram, SKF94120 and levcromakalim.
Cortijo J; Villagrasa V; Navarrete C; Sanz C; Berto L; Michel A; Bonnet PA; Morcillo EJ
Br J Pharmacol; 1996 Sep; 119(1):99-106. PubMed ID: 8872362
[TBL] [Abstract][Full Text] [Related]
6. Limitation of reperfusion injury by a monoclonal antibody to C5a during myocardial infarction in pigs.
Amsterdam EA; Stahl GL; Pan HL; Rendig SV; Fletcher MP; Longhurst JC
Am J Physiol; 1995 Jan; 268(1 Pt 2):H448-57. PubMed ID: 7840295
[TBL] [Abstract][Full Text] [Related]
7. Effect of a cyclic adenosine monophosphate phosphodiesterase inhibitor, DN-9693, on myocardial reperfusion injury.
Chang-Chun C; Matsuda H; Sawa Y; Kaneko M; Sakagoshi N; Nishimura M; Kuratani T; Amemiya A; Kawashima Y
Ann Thorac Surg; 1991 Sep; 52(3):495-9. PubMed ID: 1654868
[TBL] [Abstract][Full Text] [Related]
8. Reversal of pulmonary capillary ischemia-reperfusion injury by rolipram, a cAMP phosphodiesterase inhibitor.
Barnard JW; Seibert AF; Prasad VR; Smart DA; Strada SJ; Taylor AE; Thompson WJ
J Appl Physiol (1985); 1994 Aug; 77(2):774-81. PubMed ID: 8002527
[TBL] [Abstract][Full Text] [Related]
9. Reduction of experimental canine myocardial infarct size with prostaglandin E1: inhibition of neutrophil migration and activation.
Simpson PJ; Mickelson J; Fantone JC; Gallagher KP; Lucchesi BR
J Pharmacol Exp Ther; 1988 Feb; 244(2):619-24. PubMed ID: 2831348
[TBL] [Abstract][Full Text] [Related]
10. Sustained limitation of myocardial reperfusion injury by a monoclonal antibody that alters leukocyte function.
Simpson PJ; Todd RF; Mickelson JK; Fantone JC; Gallagher KP; Lee KA; Tamura Y; Cronin M; Lucchesi BR
Circulation; 1990 Jan; 81(1):226-37. PubMed ID: 2153476
[TBL] [Abstract][Full Text] [Related]
11. Increased adenosine concentration in blood from ischemic myocardium by AICA riboside. Effects on flow, granulocytes, and injury.
Gruber HE; Hoffer ME; McAllister DR; Laikind PK; Lane TA; Schmid-Schoenbein GW; Engler RL
Circulation; 1989 Nov; 80(5):1400-11. PubMed ID: 2553298
[TBL] [Abstract][Full Text] [Related]
12. Influence of leukopenia on collateral flow, reperfusion flow, reflow ventricular fibrillation, and infarct size in dogs.
de Lorgeril M; Basmadjian A; Lavallée M; Clément R; Millette D; Rousseau G; Latour JG
Am Heart J; 1989 Mar; 117(3):523-32. PubMed ID: 2919531
[TBL] [Abstract][Full Text] [Related]
13. Enhanced protection from renal ischemia-reperfusion [correction of ischemia:reperfusion] injury with A(2A)-adenosine receptor activation and PDE 4 inhibition.
Okusa MD; Linden J; Huang L; Rosin DL; Smith DF; Sullivan G
Kidney Int; 2001 Jun; 59(6):2114-25. PubMed ID: 11380813
[TBL] [Abstract][Full Text] [Related]
14. Isoprenaline induction of cAMP-phosphodiesterase in guinea-pig macrophages occurs in the presence, but not in the absence, of the phosphodiesterase type IV inhibitor rolipram.
Kochetkova M; Burns FM; Souness JE
Biochem Pharmacol; 1995 Dec; 50(12):2033-8. PubMed ID: 8849330
[TBL] [Abstract][Full Text] [Related]
15. Reduction of infarct size and postischemic inflammation from ATL-146e, a highly selective adenosine A2A receptor agonist, in reperfused canine myocardium.
Glover DK; Riou LM; Ruiz M; Sullivan GW; Linden J; Rieger JM; Macdonald TL; Watson DD; Beller GA
Am J Physiol Heart Circ Physiol; 2005 Apr; 288(4):H1851-8. PubMed ID: 15591104
[TBL] [Abstract][Full Text] [Related]
16. Effects of rolipram and cilostamide on renal functions and cyclic AMP release in anesthetized dogs.
Tanahashi M; Hara S; Yoshida M; Suzuki-Kusaba M; Hisa H; Satoh S
J Pharmacol Exp Ther; 1999 Jun; 289(3):1533-8. PubMed ID: 10336549
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of pig aortic smooth muscle cell DNA synthesis by selective type III and type IV cyclic AMP phosphodiesterase inhibitors.
Souness JE; Hassall GA; Parrott DP
Biochem Pharmacol; 1992 Sep; 44(5):857-66. PubMed ID: 1326964
[TBL] [Abstract][Full Text] [Related]
18. Irsogladine, an anti-ulcer drug, suppresses superoxide production by inhibiting phosphodiesterase type 4 in human neutrophils.
Kyoi T; Noda K; Oka M; Ukai Y
Life Sci; 2004 Nov; 76(1):71-83. PubMed ID: 15501481
[TBL] [Abstract][Full Text] [Related]
19. Cardioprotective effects of nicorandil.
Gross GJ; Auchampach JA; Maruyama M; Warltier DC; Pieper GM
J Cardiovasc Pharmacol; 1992; 20 Suppl 3():S22-8. PubMed ID: 1282172
[TBL] [Abstract][Full Text] [Related]
20. Modulation of rat thymocyte proliferative response through the inhibition of different cyclic nucleotide phosphodiesterase isoforms by means of selective inhibitors and cGMP-elevating agents.
Marcoz P; Prigent AF; Lagarde M; Nemoz G
Mol Pharmacol; 1993 Nov; 44(5):1027-35. PubMed ID: 8246905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
